GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
- Conditions
- Esophageal CancerHepatocellular CarcinomaCarcinoma Breast Stage IVRenal Cell CancerHead and Neck Cancers- Squamous CellGlioblastoma MultiformeTriple Negative Breast CancerSmall Cell Lung CancerHormone-refractory Prostate CancerEndometrial Cancer
- Interventions
- Drug: Sacituzumab Govitecan-hziy (SG)
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 515
- Registration Number
- NCT01631552
- Locations
- 🇺🇸
Massachusettes General Hospital, Boston, Massachusetts, United States
🇺🇸Texas Oncology Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Helen F. Graham Cancer Center, Newark, Delaware, United States
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2015-11-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 534
- Registration Number
- NCT01625338
- Locations
- 🇺🇸
Lightsource Medical/Peter J. Ruane MD, Inc., Los Angeles, California, United States
🇺🇸California Liver Institute, Los Angeles, California, United States
🇺🇸Anthony Mills MD, Inc., Los Angeles, California, United States
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 202
- Registration Number
- NCT01604850
- Locations
- 🇨🇦
Toronto Liver Centre, Toronto, Ontario, Canada
🇺🇸Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States
🇺🇸Texas Clinical Research Institute, LLC, Arlington, Texas, United States
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer
- Conditions
- Colon CancerRectal CancerMetastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 92
- Registration Number
- NCT01605318
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Helen F. Graham Cancer Center-Christiana Care, Newark, Delaware, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
- Conditions
- Hepatitis C
- Interventions
- Drug: Single Ascending Dose Cohorts GS-9620Drug: Multiple Ascending Dose Cohorts GS-9620
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 51
- Registration Number
- NCT01591668
- Locations
- 🇺🇸
Avail Clinical Research, LLC, DeLand, Florida, United States
🇵🇷Fundacion De Investigacion De Diego, Santurce, Puerto Rico
🇺🇸CliniLabs, New York, New York, United States
Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy
- Conditions
- Hepatitis B
- Interventions
- Drug: Anti-HBV nucleoside/nucleotide therapy
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT01590615
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇨🇦Vancouver General Hospital, Vancouver, British Columbia, Canada
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
- Conditions
- Hepatitis B
- Interventions
- Drug: Single Ascending Dose (SAD) Cohorts GS-9620Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 51
- Registration Number
- NCT01590654
- Locations
- 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
- Conditions
- Hepatitis BHBV
- Interventions
- Drug: Single Ascending Dose (SAD) Cohorts GS-9620Drug: Multiple Ascending Dose (MAD) Cohorts
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 49
- Registration Number
- NCT01590641
- Locations
- 🇦🇺
Royal Perth Hospital, Nedlands, Western Australia, Australia
🇨🇦Algorithme Pharma, Inc., Montreal, Quebec, Canada
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
- Conditions
- Non-Hodgkin's LymphomaChronic Lymphocytic Leukemia
- Interventions
- Drug: hLL1-DOX (IMMU-115)
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 13
- Registration Number
- NCT01585688
- Locations
- 🇺🇸
UMass Memorial Cancer Center of Excellence, Worcester, Massachusetts, United States
🇺🇸MD Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸IU Health Goshen Center for Cancer Care, Goshen, Indiana, United States
Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 416
- Registration Number
- NCT01569295
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇬🇧University College London, London, United Kingdom
🇬🇷G. Genimatas Hospital, Athens, Greece